结核病药物研发：基于机制范式的历史与演进
Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.
作者信息
Chakraborty Sumit, Rhee Kyu Y
机构信息
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, New York 10021 Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10021.
出版信息
Cold Spring Harb Perspect Med. 2015 Apr 15;5(8):a021147. doi: 10.1101/cshperspect.a021147.
Abstract
Modern tuberculosis (TB) chemotherapy is widely viewed as a crowning triumph of anti-infectives research. However, only one new TB drug has entered clinical practice in the past 40 years while drug resistance threatens to further destabilize the pandemic. Here, we review a brief history of TB drug development, focusing on the evolution of mechanism(s)-of-action studies and key conceptual barriers to rational, mechanism-based drugs.
摘要
现代结核病化疗被广泛视为抗感染研究的一项至高无上的成就。然而，在过去40年里，只有一种新型结核病药物进入临床应用，而耐药性有可能进一步破坏这场全球流行病的防控局势。在此，我们回顾结核病药物研发的简要历史，重点关注作用机制研究的演变以及合理的、基于作用机制的药物所面临的关键概念障碍。
相似文献
1
Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.结核病药物研发：基于机制范式的历史与演进
Cold Spring Harb Perspect Med. 2015 Apr 15;5(8):a021147. doi: 10.1101/cshperspect.a021147.
2
3
Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).优化背景治疗方案治疗活动期结核病与下一代苯并噻嗪酮 Macozinone (PBTZ169)。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.00840-18. Print 2018 Nov.
4
[Trends in tuberculosis treatment duration].[结核病治疗疗程的趋势]
Presse Med. 2006 Nov;35(11 Pt 2):1758-1764. doi: 10.1016/S0755-4982(06)74895-3.
5
[Response to the short-course chemotherapy in patients presenting initial resistance].[初始耐药患者对短程化疗的反应]
Bull Int Union Tuberc. 1985 Mar-Jun;60(1-2):41-3.
6
Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models.利用多状态结核病药效学和一般药效学相互作用模型评估小鼠中的药效学相互作用。
CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):787-797. doi: 10.1002/psp4.12226. Epub 2017 Oct 10.
7
[Mechanisms of the action of drugs in the short-course chemotherapy].[药物在短程化疗中的作用机制]
Bull Int Union Tuberc. 1985 Mar-Jun;60(1-2):36-40.
8
Is the treatment of WHO category I tuberculosis with 2HRZE/6HE a defensible practice?采用2HRZE/6HE方案治疗世界卫生组织分类I型结核病是否是一种合理的做法？
Int J Tuberc Lung Dis. 1999 Sep;3(9):747-8.
9
Drug-resistant tuberculosis in the Philippines.菲律宾的耐药结核病
Int J Tuberc Lung Dis. 1999 Jul;3(7):639.
10
Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates.结核分枝杆菌分离株的耐药谱和耐药水平同时增加。
Int J Tuberc Lung Dis. 2010 Nov;14(11):1436-41, i.
引用本文的文献
1
Advancing the fight against tuberculosis: integrating innovation and public health in diagnosis, treatment, vaccine development, and implementation science.推进结核病防治工作：在诊断、治疗、疫苗研发及实施科学方面整合创新与公共卫生。
Front Med (Lausanne). 2025 Aug 25;12:1596579. doi: 10.3389/fmed.2025.1596579. eCollection 2025.
2
Advancements in the design and development of pyrazoline-based antimycobacterial agents: an update and future perspectives.基于吡唑啉的抗分枝杆菌药物的设计与开发进展：最新情况与未来展望
RSC Adv. 2025 Sep 1;15(38):31360-31401. doi: 10.1039/d5ra03759j. eCollection 2025 Aug 29.
3
Hydrazides as Powerful Tools in Medicinal Chemistry: Synthesis, Reactivity, and Biological Applications.酰肼类化合物：药物化学中的强大工具——合成、反应性及生物学应用
Molecules. 2025 Jul 3;30(13):2852. doi: 10.3390/molecules30132852.
4
Unlocking potent anti-tuberculosis natural products through structure-activity relationship analysis.通过构效关系分析揭示强效抗结核天然产物
Nat Prod Bioprospect. 2025 Jul 7;15(1):44. doi: 10.1007/s13659-025-00529-4.
5
Ultrafast green synthesis of silver nanoparticles as fluorescent nanosensors for determination of isoniazid and nitrofurantoin in biological fluids and pharmaceuticals.银纳米颗粒的超快绿色合成作为荧光纳米传感器用于测定生物流体和药物中的异烟肼和呋喃妥因。
Sci Rep. 2025 May 3;15(1):15548. doi: 10.1038/s41598-025-98373-6.
6
Establishment of minimum protein standards for -derived extracellular vesicles through comparison of EV enrichment methods.通过比较细胞外囊泡富集方法建立源自[具体来源未明确]的细胞外囊泡的最低蛋白质标准。
Mycobacteria. 2025;1(1):3. doi: 10.1186/s44350-025-00003-8. Epub 2025 Apr 15.
7
Catalase-peroxidase (KatG): a potential frontier in tuberculosis drug development.过氧化氢酶-过氧化物酶（KatG）：结核病药物研发的一个潜在前沿领域。
Crit Rev Biochem Mol Biol. 2024 Dec;59(6):434-446. doi: 10.1080/10409238.2025.2470630. Epub 2025 Feb 27.
8
Progress in the role of nanoparticles in the diagnosis and treatment of bone and joint tuberculosis.纳米颗粒在骨与关节结核诊断和治疗中的作用进展
Front Med (Lausanne). 2025 Jan 24;12:1536547. doi: 10.3389/fmed.2025.1536547. eCollection 2025.
9
Bioassay-guided isolation and structure elucidation of anti-mycobacterium tuberculosis compounds from Galatella grimmii (Regel & Schmalh.) Sennikov.生物活性导向的从格林米氏乳菀（Regel & Schmalh.）Sennikov中分离抗结核化合物及结构鉴定
BMC Complement Med Ther. 2024 Oct 1;24(1):345. doi: 10.1186/s12906-024-04632-w.
10
Indole N-Linked Hydroperoxyl Adduct of Protein-Derived Cofactor Modulating Catalase-Peroxidase Functions.蛋白衍生辅因子调节过氧化氢酶过氧化物酶功能的吲哚 N-连接过氧羟胺加合物。
Angew Chem Int Ed Engl. 2024 Dec 2;63(49):e202407018. doi: 10.1002/anie.202407018. Epub 2024 Nov 4.
本文引用的文献
1
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.新型抗结核药物、方案和辅助治疗：需求、进展和未来前景。
Lancet Infect Dis. 2014 Apr;14(4):327-40. doi: 10.1016/S1473-3099(13)70328-1.
2
Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism.结核分枝杆菌对贝达喹啉的延迟杀菌反应涉及细菌代谢重塑。
Nat Commun. 2014 Feb 26;5:3369. doi: 10.1038/ncomms4369.
3
Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes.高水平乙胺丁醇耐药结核分枝杆菌通过分枝菌酸生物合成和利用途径基因中相互作用的突变而进化。
Nat Genet. 2013 Oct;45(10):1190-7. doi: 10.1038/ng.2743. Epub 2013 Sep 1.
4
Advances in the development of new tuberculosis drugs and treatment regimens.新结核病药物和治疗方案的研究进展。
Nat Rev Drug Discov. 2013 May;12(5):388-404. doi: 10.1038/nrd4001.
5
6
Infectious disease. Approval of novel TB drug celebrated--with restraint.传染病。新型结核病药物获批，庆祝但有所克制。
Science. 2013 Jan 11;339(6116):130. doi: 10.1126/science.339.6116.130.
7
Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis.对氨基水杨酸在结核分枝杆菌中作为叶酸代谢的替代底物发挥作用。
Science. 2013 Jan 4;339(6115):88-91. doi: 10.1126/science.1228980. Epub 2012 Nov 1.
8
Scaling up interventions to achieve global tuberculosis control: progress and new developments.扩大干预措施以实现全球结核病控制：进展和新动向。
Lancet. 2012 May 19;379(9829):1902-13. doi: 10.1016/S0140-6736(12)60727-2.
9
Innovation: Metabolomics: the apogee of the omics trilogy.创新：代谢组学：组学三部曲的巅峰。
Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):263-9. doi: 10.1038/nrm3314.
10
Nitazoxanide Disrupts Membrane Potential and Intrabacterial pH Homeostasis of Mycobacterium tuberculosis.硝唑尼特破坏结核分枝杆菌的膜电位和细菌内pH稳态。
ACS Med Chem Lett. 2011;2(11):849-854. doi: 10.1021/ml200157f.
Zotero 插件